Epic Sciences

Press Releases

07.30.2014

Epic Sciences announces Series C financing to advance essential cancer diagnostics for personalized medicine.

Epic Sciences announced today the completion of a $30 million Series C Preferred Stock financing. The financing included new investors RusnanoMedInvest (RMI) and Arcus Ventures, existing investors Domain Associates, Roche Venture Fund, and Pfizer Venture Investments, as well as undisclosed individual investors.

07.30.2014

Epic Sciences appoints Greg Lucier as chairman of the board of directors.

Epic Sciences announced today the appoint of Gregory T. Lucier as chairman of Epic’s board of directors. Mr. Lucier was previously chairman and CEO of Life Technologies (formerly Invitrogen). Mr. Lucier joins Epic’s board of directors to provide expertise as Epic commercializes its circulating rare cell analysis platform with special focus on the development of products and services to detect circulating tumor cells (CTCs) in cancer.

05.05.2014

Epic Sciences selected to present at Cavendish Global Health Impact Forum.

Epic Sciences, developer of novel diagnostics to personalize and advance the treatment and management of cancer, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place May 5-7 New York, NY. The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences.

04.08.2014

Epic sciences appoints Pascal Bamford, Ph.D., as vice president of product development.

Epic Sciences announced today the appointment of Pascal Bamford, Ph.D. as vice president of product development. Dr. Bamford has more than 15 years of experience in developing complex, automated diagnostic systems for digital pathology. Prior to joining Epic Sciences, Dr. Bamford served as senior project leader for Advanced Staining Assays at Ventana Medical Systems, Inc., a member of the Roche Group. Dr. Bamford is recognized as a creative innovator and project leader with a successful track record of translating new technologies into high-impact products.

01.29.2014

Epic Sciences partners with LabCorp to accelerate European clinical sample processing CTC technology.

Epic Sciences announced today an agreement with Laboratory Corporation of America® Holdings (LabCorp) to expedite sample processing for Epic's circulating tumor cell (CTC) technology to support European clinical trials.

01.29.2014

Epic Sciences and collaborators to present six novel abstracts at ASCO GU addressing the clinical applicability of Epic's CTC technology in prostate cancer.

Epic Sciences, in collaboration with the company's academic and pharmaceutical partners including Memorial Sloan Kettering Cancer Center, Institute of Cancer Research, Weill Cornell Medical College, University of Michigan, and Progenics Pharmaceuticals, will present six novel abstracts at the American Society of Clinical Oncology Genitourinary (ASCO GU) conference, taking place January 30 to February 1 in San Francisco.

02.12.2013

Epic Sciences' research in prostate cancer presented at the 2013 ASCO Genitourinary Cancers Symposium.

Epic Sciences, a private biotech company that develops breakthrough cancer diagnostics, announced the presentation of a research poster at the 2013 Genitourinary Cancers Symposium taking place February 14 to 16 in Orlando, Fla. The symposium presents the latest research in genitourinary cancers and is sponsored by three leading medical specialty societies: American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO).